Two Seas Capital LP Decreases Position in Indivior PLC (NASDAQ:INDV)

Two Seas Capital LP cut its stake in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 4.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,457,514 shares of the company's stock after selling 572,513 shares during the period. Indivior accounts for approximately 12.2% of Two Seas Capital LP's portfolio, making the stock its 2nd largest holding. Two Seas Capital LP owned approximately 9.04% of Indivior worth $154,847,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of INDV. Claret Asset Management Corp bought a new position in Indivior in the 4th quarter worth about $9,304,000. CenterBook Partners LP raised its holdings in shares of Indivior by 105.5% during the 4th quarter. CenterBook Partners LP now owns 1,147,841 shares of the company's stock valued at $14,268,000 after buying an additional 589,158 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of Indivior by 659.7% during the 4th quarter. Marshall Wace LLP now owns 506,782 shares of the company's stock valued at $6,299,000 after purchasing an additional 440,072 shares during the last quarter. SIH Partners LLLP bought a new stake in shares of Indivior in the 4th quarter valued at about $2,698,000. Finally, Kazazian Asset Management LLC purchased a new stake in shares of Indivior during the fourth quarter valued at approximately $1,706,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Stock Up 0.4%

Shares of NASDAQ:INDV traded up $0.05 during midday trading on Monday, reaching $11.26. The company's stock had a trading volume of 1,303,351 shares, compared to its average volume of 1,022,970. The firm has a 50 day moving average of $10.30 and a 200-day moving average of $10.71. The firm has a market capitalization of $1.55 billion, a P/E ratio of -32.17 and a beta of 0.98. Indivior PLC has a 12-month low of $7.33 and a 12-month high of $18.59.

Indivior (NASDAQ:INDV - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.19. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The business had revenue of $266.00 million during the quarter, compared to the consensus estimate of $240.13 million. On average, research analysts predict that Indivior PLC will post 1.22 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on INDV shares. RODMAN&RENSHAW raised shares of Indivior to a "strong-buy" rating in a report on Tuesday, January 28th. Piper Sandler lowered their price target on Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research report on Thursday, March 6th. Finally, Rodman & Renshaw initiated coverage on Indivior in a report on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price objective for the company.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.